{"id":68433,"date":"2026-06-17T22:09:27","date_gmt":"2026-06-17T14:09:27","guid":{"rendered":"https:\/\/flcube.com\/?p=68433"},"modified":"2026-06-17T22:09:28","modified_gmt":"2026-06-17T14:09:28","slug":"luye-pharmas-dual-target-candidate-ly03015-achieves-breakthrough-phase-ii-results-in-tardive-dyskinesia-with-76-5-response-rate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68433","title":{"rendered":"Luye Pharma&#8217;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Luye Pharma Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>) announced that its <strong>Category 1 candidate drug LY03015<\/strong> has met the primary endpoint in a <strong>China Phase II clinical trial<\/strong> for the treatment of <strong>tardive dyskinesia (TD)<\/strong>. The world&#8217;s first innovative drug targeting both <strong>vesicular monoamine transporter 2 (VMAT2)<\/strong> and <strong>Sigma-1R<\/strong> demonstrated a breakthrough <strong>76.5% response rate<\/strong> in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-milestone\" class=\"wp-block-heading\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Luye Pharma Group Limited (HKG: 2186)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>LY03015 \u2013 Category 1 innovative drug<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase II, multicenter, randomized, double-blind, placebo-controlled<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Tardive dyskinesia (TD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>121 patients with moderate-to-severe TD<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>6 weeks<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Response rate measured by Abnormal Involuntary Movement Scale (AIMS)<\/td><\/tr><tr><td><strong>Highest Response Rate<\/strong><\/td><td>76.5% (20 mg dose group)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-dual-target-innovation\" class=\"wp-block-heading\">Dual-Target Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-Class:<\/strong> World&#8217;s first drug entering clinical development targeting both VMAT2 and Sigma-1R simultaneously<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Potently reduces dopamine release from presynaptic neurons while promoting synaptic remodeling and repairing synaptic connections<\/li>\n\n\n\n<li><strong>Dual Effects:<\/strong> Combines immediate symptom control with potential pathological improvement<\/li>\n\n\n\n<li><strong>Additional Indications:<\/strong> Also being developed for chorea associated with Huntington&#8217;s disease (HD)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-differentiation\" class=\"wp-block-heading\">Clinical Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Population:<\/strong> Addresses TD caused by long-term antipsychotic medication use<\/li>\n\n\n\n<li><strong>Disease Burden:<\/strong> Hyperkinetic movement disorder significantly impacting quality of life<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> Limited effective options with suboptimal response rates in existing therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-phase-ii-results-amp-dose-response-analysis\" class=\"wp-block-heading\">Phase II Results &amp; Dose-Response Analysis<\/h2>\n\n\n\n<h3 id=\"h-efficacy-outcomes-by-dose-group\" class=\"wp-block-heading\">Efficacy Outcomes by Dose Group<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>5 mg group:<\/strong> 25.9% response rate<\/li>\n\n\n\n<li><strong>10 mg group:<\/strong> Statistically significant improvement vs. placebo (P &lt; 0.01)<\/li>\n\n\n\n<li><strong>20 mg group:<\/strong> 76.5% response rate with statistically significant difference vs. placebo (P &lt; 0.01)<\/li>\n\n\n\n<li><strong>Dose-Response Relationship:<\/strong> Clear correlation between dose escalation and improved response rates<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-safety-amp-tolerability-profile\" class=\"wp-block-heading\">Safety &amp; Tolerability Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rebound Effect:<\/strong> Relatively small rebound effect observed after drug discontinuation<\/li>\n\n\n\n<li><strong>Overall Safety:<\/strong> Good safety and tolerability maintained throughout the 6-week treatment period<\/li>\n\n\n\n<li><strong>Adverse Events:<\/strong> No serious safety concerns reported in any dose group<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TD Market Opportunity:<\/strong> Affects approximately 500,000+ patients in China alone, with limited treatment options<\/li>\n\n\n\n<li><strong>Breakthrough Potential:<\/strong> 76.5% response rate represents substantial improvement over current standard-of-care therapies<\/li>\n\n\n\n<li><strong>First-Mover Advantage:<\/strong> Dual-target mechanism provides significant competitive differentiation in neuropsychiatric disorders<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Category 1 designation in China supports expedited development and potential premium pricing<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Successful China data may support international regulatory filings for both TD and Huntington&#8217;s disease indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The exceptional Phase II results position LY03015 as a potential game-changer in the treatment of tardive dyskinesia, addressing a significant unmet medical need with unprecedented efficacy. Luye Pharma&#8217;s dual-target approach represents a paradigm shift from symptomatic management to potential disease modification in movement disorders. The clear dose-response relationship and favorable safety profile support advancement to Phase III development, while the Category 1 innovative drug status in China provides substantial regulatory and commercial advantages. This breakthrough also validates Luye&#8217;s innovative R&amp;D capabilities in complex neurological disorders beyond its traditional psychiatric franchise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to Phase III trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061601853_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061601853_c.\"><\/object><a id=\"wp-block-file--media-7142b83b-c5a9-4cf2-b69e-4fcf1c9f2328\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061601853_c.pdf\">2026061601853_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061601853_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7142b83b-c5a9-4cf2-b69e-4fcf1c9f2328\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,1023,219],"class_list":["post-68433","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-2186","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye Pharma&#039;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world&#039;s first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68433\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma&#039;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate\" \/>\n<meta property=\"og:description\" content=\"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world&#039;s first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68433\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T14:09:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T14:09:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma&#8217;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate\",\"datePublished\":\"2026-06-17T14:09:27+00:00\",\"dateModified\":\"2026-06-17T14:09:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433\"},\"wordCount\":526,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 2186\",\"Luye Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68433#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68433\",\"name\":\"Luye Pharma's Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T14:09:27+00:00\",\"dateModified\":\"2026-06-17T14:09:28+00:00\",\"description\":\"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world's first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68433\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68433#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma&#8217;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma's Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate - Insight, China&#039;s Pharmaceutical Industry","description":"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world's first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68433","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma's Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate","og_description":"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world's first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.","og_url":"https:\/\/flcube.com\/?p=68433","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T14:09:27+00:00","article_modified_time":"2026-06-17T14:09:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68433#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68433"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma&#8217;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate","datePublished":"2026-06-17T14:09:27+00:00","dateModified":"2026-06-17T14:09:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68433"},"wordCount":526,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 2186","Luye Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68433#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68433","url":"https:\/\/flcube.com\/?p=68433","name":"Luye Pharma's Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T14:09:27+00:00","dateModified":"2026-06-17T14:09:28+00:00","description":"Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world's first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68433#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68433"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68433#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma&#8217;s Dual-Target Candidate LY03015 Achieves Breakthrough Phase II Results in Tardive Dyskinesia with 76.5% Response Rate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68433"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68433\/revisions"}],"predecessor-version":[{"id":68435,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68433\/revisions\/68435"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}